AKRX:NSD-Akorn, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 0.64

Change

-0.10 (-13.51)%

Market Cap

USD 0.06B

Volume

1.31M

Average Target Price

USD 2.00 (+212.50%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-27 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

-0.66 (-4.25%)

USD7.68B 496.00 6.04
MNTA Momenta Pharmaceuticals, Inc

-1.62 (-5.72%)

USD3.13B N/A -9.26
CRON Cronos Group Inc

-0.03 (-0.47%)

USD1.87B 11.60 N/A
IRWD Ironwood Pharmaceuticals, Inc

-0.28 (-2.78%)

USD1.55B 71.01 14.33
PCRX Pacira BioSciences, Inc

-0.71 (-2.19%)

USD1.36B 961.92 26.99
TCDA Tricida, Inc

-0.93 (-3.85%)

USD1.20B N/A -5.02
SUPN Supernus Pharmaceuticals, Inc

-0.20 (-1.23%)

USD0.87B 7.92 5.96
TLRY Tilray, Inc

+1.20 (+15.19%)

USD0.82B N/A -4.50
PAHC Phibro Animal Health Corporati..

+0.24 (+1.20%)

USD0.81B 21.30 11.21
AMPH Amphastar Pharmaceuticals, Inc

-0.32 (-2.23%)

USD0.63B 13.96 35.27

ETFs Containing AKRX

Symbol Name Weight Mer Price(Change) Market Cap
PQSV PGIM QMA Strategic Alpha .. 0.17 % 0.29 %

-1.55 (-4.62%)

USD8.88M

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -57.33% 12% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.33% 12% F 9% F
Trailing 12 Months  
Capital Gain -81.12% 19% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.12% 19% F 6% F
Trailing 5 Years  
Capital Gain -98.68% 3% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.68% 3% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain -33.21% 15% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.21% 15% F 6% F
Risk Return Profile  
Volatility (Standard Deviation) 41.91% 44% F 28% F
Risk Adjusted Return -79.23% 20% F 8% F
Market Capitalization 0.06B 34% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 30.20 46% F 28% F
Price/Book Ratio 0.26 98% A+ 94% A
Price / Cash Flow Ratio -1.64 58% F 70% C-
EV/EBITDA 81.47 2% F 2% F
Management Effectiveness  
Return on Equity -66.88% 46% F 18% F
Return on Invested Capital 0.02% 72% C- 41% F
Return on Assets -2.73% 70% C- 35% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.83 61% D- 51% F
Short Percent 9.81% 44% F 28% F
Beta 1.73 37% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector